Assess the incidence and rates of resistant pathogens prior to and during the COVID-19pandemic.
The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens.
Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae
(ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus
aureus (MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI)
will be higher in the pandemic time period (Pandemic, March 2020 - February 2025)
compared to the pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).
Inclusion Criteria:
- • Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist
Charlton, or Methodist Dallas Medical Centers between March 2018 and August 2021.
- >18 years old
Exclusion Criteria:
- • Outpatient visit
- Not admitted to an inpatient or observation status
Methodist Dallas Medical Center
Dallas 4684888, Texas 4736286, United States
Mathew Crotty, PharmD, Principal Investigator
The Methodist Hospital Research Institute